Epidemiology of cardiovascular-kidney-metabolic syndrome
Three drug classes now offer proven benefits across heart, kidney, and metabolic health simultaneously, though cost and access barriers remain significant hurdles.
A Nature Reviews Nephrology review from NYU establishes the epidemiological framework for CKM syndrome (AHA 2023 definition), documenting that most adults globally have ≥stage 1 CKM, with escalating morbidity through stage 4; GLP-1 RAs, SGLT2i, and finerenone offer multisystem benefits but cost and access barriers limit uptake. The review synthesizes genetic, dietary, environmental, and social determinants while identifying priority areas for prevention and equity.
What the study was
- Study design
- Comprehensive narrative epidemiological review
- Population
- Global adult population; CKM syndrome stages 0-4; demographic and socioeconomic analyses
- Category
- Public Health
- Maturity
- Validated
- Journal
- Nature Reviews Nephrology
Why it surfaced
Tier-1 journal (Nature Reviews Nephrology) comprehensive CKM epidemiology review directly synthesizing GLP-1/SGLT2/MRA evidence for the cardiometabolic watchlist; CKM staging framework increasingly important for clinical practice.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.